Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival
FDA Approves Afinitor-Aromasin Regimen For Advanced HER2-Negative Breast Cancer
Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints
Upper Endoscopy Most Effective When Performed in 3-Year Intervals
Women Who Concieve Using Fertility Drugs Have a Higher Risk Of Breast Cancer Than Non-Users
Variation in Breast Density May Be Strong Risk Factor
Study: Molecular Breast Imaging Can Be As Effective as MRI
Mammography Had Limited Impact Among Swedish Women Age 40-69
High Vitamin E Consumption Can Lower Liver Cancer Risks
Gene Expression Test Accurately Classifies “Inconclusive” Samples
CAP, ASCCP Recommendations Standardize Lesion Terminology
NCI-Approved CTEP Trials For The Month of July
Trending Stories
- Mikaela Naylon Give Kids a Chance Act nixed by Senate
- House passes Mikaela Naylon Give Kids a Chance Act—next step, the Senate
- Should I have a drink tonight?
In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in - Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- Testing for asbestos in talc-based cosmetics seems like a no-brainer—why did FDA withdraw a rule to standardize it?
- The Cancer Letter’s most-read stories of 2025
As MAHA-led policies took hold, oncology navigated through uncertainty and turmoil
